University of Pennsylvania

ScholarlyCommons
Dental Theses

Penn Dental Medicine

Fall 12-19-2019

Gingival MSCs Improve Bone Phenotype in Ovariectomy-Induced
Osteoporosis via Programmed Cell Death Pathway
Sultan Alghaithi
University of Pennsylvania, alsult@upenn.edu

Follow this and additional works at: https://repository.upenn.edu/dental_theses
Part of the Biological Phenomena, Cell Phenomena, and Immunity Commons, Cell Biology Commons,
Medical Immunology Commons, and the Periodontics and Periodontology Commons

Recommended Citation
Alghaithi, Sultan, "Gingival MSCs Improve Bone Phenotype in Ovariectomy-Induced Osteoporosis via
Programmed Cell Death Pathway" (2019). Dental Theses. 49.
https://repository.upenn.edu/dental_theses/49

This paper is posted at ScholarlyCommons. https://repository.upenn.edu/dental_theses/49
For more information, please contact repository@pobox.upenn.edu.
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Abstract
Estrogen deficiency-related osteoporosis is a skeletal system disorder that affects women after
menopause taking a toll on financial and health institutions. Gingival Mesenchymal Stem cells (GMSCs)
are a distinctive population of dental tissue-derived stem cells that possess uniquely high proliferation
abilities and are capable of self-maintenance and multipotent differentiation. Their use has been
investigated in different disease model applications, including cutaneous wound healing models, colitis,
and allergy-related inflammatory disease models, but their effect on the bone phenotype of ovariectomyinduced osteoporosis hasn’t been explored. In our study, we show that a single systemic infusion of
GMSCs elevated the bone mass reduction caused by Ovariectomy (OVX)-induced osteoporosis in both
the femurs and mandibles of OVX mice, they also successfully rescued the function of the defective
endogenous population of Bone Marrow Mesenchymal Stem Cells (BMMSCs). We saw that the systemic
infusion of GMSCs exerted an immunomodulatory effect on the host, leading to the elevation of Tregulatory lymphocytes (T-regs) and the downregulation of T helper type 1 lymphocytes (Th1) levels in
recipient OVX mice. Mechanistically, PD-1/PD-L1 is a popular cellular death pathway being heavily
investigated in multiple research fields, In our study, we found that GMSC expresses PD-L1 and that the
improved bone phenotype resulting from the GMSC infusion was via the programmed cell death (PD-1/
PD-L1) pathway triggering activated T-cell apoptosis in the OVX mice, eventually resulting in an
improvement of the bone phenotype.
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Abstract

Menopause, an event that occurs in all women’s life cycle, attributes
physiologically to a decreased ovarian function, and an associated decline in the
female reproductive hormones. Manifestations include hot flashes, sleep
disturbances, anxiety, depression, and other changes. A common disease
affecting post-menopausal women is osteoporosis or “estrogen-deficiency related
osteoporosis.” Osteoporosis is a skeletal system disorder where bone mineral
density progressively decreases, which in turn increases the risk of fragility related
fractures. The underlying mechanism behind the estrogen-related osteoporosis, in
general, is through estrogen being a key regulator of bone remodeling and
regulating cytokines. When that balance is disrupted due to the lack of estrogen in
menopause, an intensified bone resorption rate takes place without the adequate
formation of new bone, correlated with the inflammatory nature of the postmenopausal osteoporosis disorder. Multiple treatment modalities are utilized for
the treatment and management of osteoporosis, but there are drawbacks that
confound their use. Among several efforts and reports on alternative methods and
approaches for better treatment options in osteoporosis and bone diseases,
cellular therapy, a promising method which was profoundly investigated, has
evolved noticeably in recent years as a powerful investigation tool in the field of
bone biology, and related bone disorders.
Mesenchymal Stem Cells (MSCs) are adult stem cells that act as a viable source
of cell for cell replacement to treat bone disease due to their inherent properties of
self-renewal and plasticity. Another benefit they have is their potent
immunomodulatory ability to induce immunological tolerance in the recipient host,
which makes them a desired tool for investigations in developing new treatment
modalities for immune-related diseases. Dental tissue-derived stem cells are stem
cells harvested from the oral cavity, with several promising ongoing investigated
applications including bio-root engineering, regeneration of periodontal defects,
pulpal tissue engineering, and calvarial defects regeneration and they show
promising outcomes. In this thesis project, we investigate the application and
properties of Gingival Mesenchymal Stem Cells (GMSCs). These cells are adult,
tissue-specific stem cells with several reported clinical applications in multiple
murine disease models, including wound healing models, colitis models, and
allergy-related inflammatory disease models, and the results were promising. The
availability of GMSCs is also considerably high, and there is reduced morbidity
associated with their harvesting procedures in comparison to other types of stem
iv

cells. GMSCs possess immunomodulatory properties and can modulate the
microenvironment of the recipient host and are capable of multipotent
differentiation into multiple cell types. These benefits of GMSCs prompted us to
further want to explore their therapeutic effect in a chronic inflammatory disease
model, the estrogen deficiency-induced osteoporosis model.
In this dissertation, we investigated the application of GMSCs as a novel cellular
therapeutic approach in an attempt to ameliorate the bone phenotype of estrogen
deficiency-induced osteoporosis in the OVX mouse model. Our findings
demonstrate that the single transplantation of GMSCs was able to markedly
improve the bone phenotype, as seen in both the femurs and mandibles of OVX
mice. In addition to that, our investigations also showed that the GMSCs
transplantation was able to rescue the osteogenic functions of the endogenous
population of Bone Marrow Mesenchymal Stem Cells (BMMSCs) in the recipient
ovariectomized mice. Furthermore, to explore the mechanisms underlying the
improved bone phenotype and inflammatory state associated with the estrogeninduced osteoporosis model, we examined possible pathways that may be
involved. We showed that GMSCs exerted an immunoregulatory effect on the
recipient host via the PD-L1/PD-1 pathway. Using the siRNA approach to
knockdown PD-L1 in GMSCs (siPdl1 GMSCs) or an anti-PDL1 drug
(Atezolizumab) treatment, we showed a diminished effect of the GMSCs infusion
on the OVX bone phenotype, suggesting the role of PD-L1 as an immune
checkpoint in the GMSCs-mediated effect in the ovariectomized mouse model.
Furthermore, at the cellular level, GMSCs-treated mice showed a decreased
expression of Th1, Th17, and an increase in the expression of T-reg as compared
to OVX mice. On the other hand, siPdl1 GMSCs-treated mice displayed similar
expression of Th1, T-reg, and a decreased expression of Th17 as compared to
OVX mice.
In conclusion, cell-based therapy using GMSCs can improve the osteoporotic bone
phenotype, as well as rescue the function of the endogenous populations of
BMMSCs in the estrogen deficiency OVX mouse model of osteoporosis, and the
PD-L1/PD-1 pathway plays a role in the GMSCs mediated effects seen in the OVX
mice.
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Introduction
Osteoporosis:
The national institute of health (NIH) describes osteoporosis as a skeletal
system disorder occurring due to the reduction of bone density, which in turn leads
to an increased risk of bone fractures (1). The disease resembles a growing
worldwide concern, and it is estimated that today, over 200 million people
worldwide are diagnosed with the disease (2). From a physiological point of view,
the disease of osteoporosis occurs when there is an imbalance between bone
formation and bone resorption rates, this could happen by either a decrease in the
bone formation rates or an increase in bone resorption rates. The disease is also
a chronic and silent disease in nature, up until it reaches the point of clinical
detection or manifestation or until an incident of bone fracture occurs (3).
The diagnosis of the disease is a process that mainly involves an overall
assessment of the subject’s bone mineral density value (BMD), which is measured
by different available diagnostic means, such as the dual-energy x-ray
absorptiometry (DXA) scan. Then if the value obtained is equal to or more than 2.5
standard deviations less than the reference young adult mean value, they would
be diagnosed with osteoporosis (4). Several risk factors for fractures are also taken
into consideration when diagnosing patients, these multiple known risk factors for
osteoporosis have been long investigated as well as reported in the literature over
the years. Some of these factors leading to low bone mineral density and
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osteoporosis are age, sex, race, estrogen levels, previous fragility-related
fractures, and others (Fig.1). These investigations and researches aim to
progressively better understand the relation of these risk factors to osteoporosis
and fractures because of the considerable magnitude of the disease and impact of
disability on societies as well as the significant toll of the increased financial weight
for the costs associated with the treatment of osteoporosis-related fractures (5-9).

Figure 1. Risk factors for osteoporosis. Risk factors for osteoporosis and low
bone mineral density. (Figure adapted from Wickham 2011(9))
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Menopause and postmenopausal osteoporosis:
Menopause is a risk factor for developing osteoporosis. The world health
organization (WHO) defines menopause as "the permanent cessation of
menstruation resulting from the loss of ovarian follicular activity." Moreover, it is
estimated that in the united states, the yearly number of women reaching
menopause is around 1.5 million, while menopause occurs in every woman's life
cycle, it is marked beginning with the first missed period of 12 consecutive months
of menstrual cycle termination. The average age for which menopause occurs is
around 50 years, and it is characterized by multisymptomatic changes, mainly
vasomotor symptoms such as hot flashes, night sweats, and flushes. It is also
accompanied by a decrease in ovarian hormones, mainly Estrogen, this decline
reaches its maximum level of decrease 3 to 4 years from the last occurring
menstrual cycle (10-12). The effects of this decrease also involve the skeletal
system and are linked to osteoporosis in post-menopausal women leading to a
disruption of the existing balance between bone formation and bone resorption
rates. Furthermore, even though the mechanism behind it is yet to be fully
understood, the effect of Estrogen on the bone is known to be primarily by its
modulation capabilities of cytokine production and blocking osteoclastogenesis, as
well as indirectly increasing the absorption of calcium from the intestines, and
decreasing the renal output of calcium (13,14).
In addition to the effect of Estrogen on the decrease in bone resorption
rates, it is further known to promote osteoclast apoptosis directly by the increase
in TGF-β production (15). In menopause, when the levels of estrogen decrease,
3

an increase in some pro-inflammatory cytokines has been described, which in turn,
increases osteoclast formation and inhibits their apoptosis; it also influences other
cytokines affecting osteoclast differentiation such as IL-6, Macrophage ColonyStimulating Factor (M-CSF), and Granulocyte-Macrophage Colony-Stimulating
Factor (GM-CSF) (16,17). In addition to the effect on cytokines, the immune
system's T-lymphocytes are recognized too as key players in modulating the
adverse effects on the bone from Estrogen deficiency and the noted increase in
the inflammatory cytokines by the production of IFN-γ, and TNF-α which in turn
intensifies the effect of M-CSF and RANKL induced osteoclastogenesis (18,19).
Overall, estrogen has an anti-inflammatory effect and it has been shown that OVX
mice exhibit an increase in inflammation and a shortened life span. (20)

Current treatment modalities:
Multiple approaches to the intervention of osteoporosis have been reported
in the literature. Those interventions could be classified as either pharmacological
or non-pharmacological based interventions. Non-pharmacological interventions
incorporate dietary and lifestyle recommendations that include calcium or vitamin
D intake and exercise routines (1). On the other hand, pharmacologic based
interventions like antiresorptive agents include the widely-used bisphosphonates
class of medications, a class of drugs that reduces bone resorption by increasing
the apoptosis of osteoclasts (21). Some of the different bisphosphonates class
drugs used for the treatment of osteoporosis are alendronate (22), Risedronate
(23), and Ibandronate (24). These drugs have been evaluated for their use in post4

menopausal osteoporosis and reported to be efficient. However, although their
efficiency in treatment, their use has been connected to complications such as
osteonecrosis of the jaw and atypical femur fractures (25,26). Another class of
antiresorptive agents that have been used in osteoporosis treatment includes
Estrogens and selective estrogen receptor modulators (SERMs) (27,28). In
addition to the reported drawbacks that are linked to bisphosphonates, with
hormonal replacement therapy, there have been reports of their association with
breast cancer and some cardiovascular events (29,30).
Moreover, an additional pharmacological class of drugs available are the
anabolic agents, these act on the enhancement of bone formation rates rather than
decreasing the bone resorption rates, an excellent example for anabolic agents is
the parathyroid hormone (PTH). It is a well-known potent inducer of bone matrix
synthesis, and it increases osteoblast activation while decreasing their apoptosis
(31). Its use has been investigated in the treatment of osteoporosis, and its use in
both the animal and human models and the animal model shows improvement in
the bone mass and strength, those in human trials involving both genders show a
pronounced increase in the spinal bone mineral density in contrast to those
reported with antiresorptive agents (32). However, a reported setback of PTH
includes the fact that an incidence of osteosarcoma was reported when studied in
animals for two years period of use in a different variety of doses of PTH. Thus,
recommendations have been made against its use for prolonged periods of time
(33). Considering these setbacks that might be a limitation to the utilization of these
medications, there is a constant need for the development of novel treatment
5

approaches as further viable options in the management and treatment of
osteoporosis. Moreover, with the available current day advancements revolving
around cell therapy applications in the field of research and bone diseases, a cell
therapy-based approach without adverse effects or detrimental drawbacks would
be a promising alternative method to be utilized as a novel treatment in the
management and alleviation of osteoporosis and potentially other chronic
illnesses.

Cell therapy and stem cells:
The term cell therapy is prescribed by the American Society of Gene & Cell
Therapy (ASGCT) as "the administration of live whole cells or maturation of a
specific cell population in a patient for the treatment of a disease" (34). Their
application is continuously investigated in disease applications and stem cells are
believed to be a valuable source in cell therapy of bone diseases due to their ability
to directly replace damaged tissues as well as their influence on cellular
mechanisms of recovery (35). Mesenchymal stem cells (MSCs) were first reported
around the 1960s by A.J. Friedenstein; it was when the observation he made was
that bone marrow cells contain a population of cells that were capable of selfmaintenance and to differentiate into multiple mesenchymal cell lineages (36). In
addition to self-maintenance, these stem cells are cells that are available after
birth; they are multipotent, and capable of giving rise to various cell types, including
those of mesodermal (i.e., bone or cartilage cells), endodermal (i.e., muscle cells),
and ectodermal (i.e., epithelial cells) lineages (Fig.2) (37,38). Cluster
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Differentiation molecules (CD) are amongst the methods used in the process of
identifying stem cells. Some of the markers that are commonly used to identify
MSCs include, CD105, CD73, CD44, CD90, CD71, CD271, and the STRO-1
antibody also recognizes them (38).

As for their sources, MSCs have been

isolated and mainly named after their origin, they have been harvested from
multiple parts in the body, primarily from bone marrow and it is the most common
source of MSCs, other sources are the adipose tissues, placenta, umbilical cord,
Wharton's jelly, and dental tissues (39). Both MSCs isolated from bone marrow
and dental-tissues fit the criteria set by the international society for cellular therapy
to define multipotent mesenchymal stem cells (40). Those isolated from bone
marrow are reported to be able of giving rise to different cell types such as
osteocytes,

chondrocytes,

adipocytes,

hepatocytes,

neuronal

cells,

cardiomyocytes, and pancreatic cells. Additionally, those derived from dentaltissues are reported to have the capacity to differentiate into osteocytes,
chondrocytes, adipocytes, pancreatic cells, melanocytes, and neuronal cells
(39,41). These multipotential differentiation characteristics made stem cells an
attractive treatment option for investigations in disease research fields. The
National Institute of Health (NIH) currently reports on clinicaltrials.gov over a
thousand clinical trials in different investigation phases ranging from phase I to
phase IV investigating and related to MSC cell therapy. Trials reported include
researches in the fields of bone defects in different regions, cutaneous wounds,
urinary system cartilaginous defects, cardiovascular disorders, autoimmune
diseases, liver diseases, and many other chronic illnesses (42).

7

Figure 2. Different potential cell lineages of MSCs. Potential for differentiation
of BMMSCs to give rise to different cell types. (Diagram adapted from Uccelli 2008
(38))

Dental tissue derived stem cells:
In addition to the previously mentioned different sources for isolation of stem
cells, it is reported in the literature that stem cells derived from the oral cavity
include several types of cells including Dental Pulp Stem Cells (DPSCs) (43), Stem
Cells from Human Exfoliated Deciduous Teeth (SHED) (44), Periodontal Ligament
8

Stem Cells (PDLSCs) (45), Stem Cells from Apical Papilla (SCAP) (46), Dental
Follicle Precursor Cells (DFPCs) (47), Gingival Mesenchymal Stem Cells (GMSCs)
(48), and a more recently reported type that was discovered in 2013 by Marrelli et
al and is considered an additional source of stem cells which is human periapical
cysts and it was named Human Periapical Cyst-Mesenchymal Stem Cells (hPCyMSCs) (49).
These dental tissues derived stem cells can give rise to lineages like those
of BMMSCs, and they are shown to be neural crest-derived in origin, their
application has been investigated in both oral and non-oral applications. Some of
their oral applications investigated include bio-root engineering, regeneration of
periodontal defects, pulp tissue engineering, and regeneration (41). They have
also been evaluated in non-oral cell therapy applications. Some of these
regenerative investigations include using scaffolds seeded with DPSCs to
accelerate defect healing and bone regeneration in calvaria of rats. (50), DPSCs
were also reported to differentiate into corneal epithelial progenitors when seeded
in contact lenses and delivered to human corneas indicating their potential
application in eye diseases (51).
Moreover, SHED’s application was investigated in Systemic Lupus
Erythematosus (SLE) mouse model and showed a successful reversal of the
disorders associated with the disease as well as elevating the levels of Tregulatory cells (52). SHED’s application was also investigated in multiple disease
models, including Parkinson’s rat models, Liver disease mice models, as well as
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Diabetes mellitus mice models, and researchers report promising outcomes (5355).
In the field of bone disease research, amongst the multiple animal models
available for the investigation of osteoporosis, a popular well-established model is
the ovariectomy model (OVX). It is known to be a reliable model for research. The
ovaries are surgically removed, which induces estrogen deficiency, and the animal
loses 50% of their cancellous bone because of the procedure resembling an
osteoporotic phenotype, one other model available is the glucocorticoid treated
model where the animal is treated with glucocorticoids for seven days to induce
bone loss. Investigators have widely utilized These types of small animals in the
research of bone diseases (56). Up to date, the use of stem cells has been
investigated for osteoporosis treatment from multiple sources, such as umbilical
cord blood-derived stem cells, bone marrow mesenchymal stem cells, and adipose
tissues derived stem cells (57). Several investigations utilized the use of BMMSC
in the treatment of osteoporosis by using the OVX animal model as well. Hsiao et
al. reported the use of systemic injection of labeled mice bone marrow MSCs and
that they have been shown to home the bone marrow of the host two months postinjection and improve the bone density and volume in the OVX mouse model (58).
Liu et al. also reported the use of human BMMSCs in the OVX mouse model and
showed that single transplantation of stem cells successfully prevented the early
phases of bone loss as well as significantly downregulated the levels of Th1, T17
and upregulated T-reg cells (59). These results verify the familiar role of BMMSCS
in immunomodulation and their ability to suppress the proliferation of T-cells (60).
10

In addition to that, the ability of BMMSCs to inhibit proinflammatory cytokines such
as TNF-α and IFN-γ and increase the expression of anti-inflammatory cytokines
such as IL-10 has also been reported (61). These characteristics of BMMSCs
capability of improving the osteoporotic bone phenotype of OVX animals made
them an attractive tool for further investigation and development in cell therapy.
However, although BMMSCs are the most commonly researched source of stem
cells, the morbidity associated with their collection is high, and the accessibility to
them and their harvesting procedure is of a complex nature, as well as the number
of cells able to be collected from the tissues is considered low (62). These reasons,
amongst others, led investigators to explore further and research for alternative
sources to use in cell therapy disease research.

Gingival mesenchymal stem cells:
On the other hand, Gingival Mesenchymal Stem Cells (GMSCs) are also
dental tissues derived stem cells isolated from the gingiva, and they have been
characterized by self-renewal properties, multipotent differentiation abilities, and
immunomodulatory effects and their availability is of abundance as they are easily
obtained from donor gingival tissue (48,63,64). Their application has been
investigated in different experimental disease models. Some of their uses include
their application in the experimental colitis model, as reported by Zhang et al. In
an induced dextran sulfate sodium (DSS) model of colitis representing an
inflammatory bowel disease (IBD). A single infusion of GMSCs ameliorated the
disease, lowered the rate of T-helper lymphocytes recruitment, increased the
11

levels of T-regulatory lymphocytes. Additionally, in chemotherapy-induced oral
mucositis model, alleviation of the disease was evident by the reversal of body
weight loss and the restoration of the broken down epithelial lining (65). In another
disease model, a wound healing model that utilizes excisional cutaneous wounds
was studied, accelerated wound closure was achieved, also a reduction in the local
inflammatory cells and pro-inflammatory cytokines (64). GMSCs were also
reported to successfully regenerated boney defects in the Mandible and Calvaria
of rats by their direct participation in bone formation, and the recruitment of bone
progenitor cells (66). The hallmark of stem cells from of gingiva in different disease
models is that those Gingival Stem Cells achieved promising outcomes mainly
through the ability to decrease the levels of pro-inflammatory cytokines, and Thelper lymphocytes as well as the increase of T-regulatory lymphocytes (48,64).
And, even though their use has been evaluated in the utilization of the mentioned
above disease models, the therapeutic effect of their use as a potential approach
for the amelioration and improvement of boney effects of osteoporosis has not
been assessed in the Ovariectomy model.
In this dissertation, we hypothesized that the systemic infusion of GMSCs
would improve the osteoporotic bone phenotype of the estrogen deficiency related
inflammatory mouse model, rescue the overall functions of the endogenous
populations of BMMSCs of the study animals, and that the GMSCs transplantation
would exert an immunoregulatory effect on T-cells and would induce
immunological tolerance leading to the improvement of the bone phenotype, we
also hypothesized the involvement of a cell death pathway as mechanism of action
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behind the GMSCs-mediated influence on T-cells. To test our hypotheses and
explore and understand the effects of the GMSCs treatment on the osteoporotic
mouse model, we proposed three specific aims as elaborated next.
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Specific Aims

1- Specific Aim #1: To investigate whether stem cell-based therapy using
a single systemic transplantation of GMSC can improve the bone
phenotype in the estrogen deficiency, ovariectomy (OVX)-induced
osteoporosis mouse model.

2- Specific Aim #2: To explore the therapeutic effects of GMSCs in the
OVX mouse model and to test the ability of GMSCs to rescue the biological
functions of the defective endogenous BMMSC populations in the
osteoporotic OVX mice.

3- Specific Aim #3: To delineate the mechanisms underlying the rescue of
bone

phenotype

in

osteoporotic

OVX

mice,

specifically

the

immunomodulatory effect of GMSCs.
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Materials and Methods

Animals and the induction of estrogen-deficiency related osteoporosis:
The Ovariectomized mouse model is a well-established model for bone disease
research representing estrogen deficiency-related osteoporosis as a result of the
loss of ovaries. Bone disease research utilizes C3H/HeJ mice due to their increase
trabeculation in the bone. All animal experiments described in this dissertation
were performed under institutionally approved protocols for the use of animal
research under protocol #805478 approved by the University of Pennsylvania
Institutional Animal Care and Use Committee (ICAUC). In order to explore the
effect of GMSCs on the bone phenotype of ovariectomized mice, 8-week-old
female C3H/HeJ mice were purchased from Jackson Labs (Bar Harbor, ME, USA).
Mice were then divided into three age-matched groups as illustrated in (Fig.3)

No surgery

Ovariectomy

Ovariectomy

No cell Tx.

No cell Tx.

GMSC Tx.

Figure 3. Study groups. Illustration of study groups assignment.
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First group was the negative control group where the mice were not subjected to
any surgical procedure nor treatment serving as a negative control. The second
group was the OVX group, this group of mice received surgical ovariectomy
procedure of both ovaries but did not receive any cellular infusion serving as the
positive control group. The third group was the GMSC- treatment group, these
mice received surgical ovariectomy of both ovaries then a single infusion of
GMSCs as outlined in the following experimental timeline described in (Fig 4). The
GMSC-treated mice group was systemically infused with 2×105 mouse GMSCs.

Figure. 4 Experimental Timeline. Ovariectomy procedure done at 9 weeks to
designated groups, GMSCs were injected into designated group intravenously via
the tail vein.

The ovariectomy procedure was performed on C3H/HeJ mice using an
electrocautery machine for maximum hemostasis achievement. A Two-weeks
period was allowed for the OVX phenotype to be properly established; all mice
were sacrificed at 4 weeks post-injection for subsequent examination. The sample
size of the animals used in the experiments were at least an n = 5 in each group.
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Additional Prkdcscid mice (females, six weeks old) were purchased from Jackson
Labs (Bar Harbor, ME, USA) for the experiment of testing BMMSC transplantation
into immunocompromised mice.

For testing of drug Atezolizumab, 8-week-old female C3H/HeJ mice were
purchased from Jackson Labs (Bar Harbor, ME, USA). After dividing mice to two
groups of n=5. The ovariectomy procedure was performed mice also using an
electrocautery machine. A Two-weeks period was allowed for the OVX phenotype
to be properly established, after two weeks the injection of GMSCs was infused
into both groups, The drug group further received a systemic injection of
Atezolizumab anti-PDL1 drug obtained from Invivogen USA (#hpdl1-mab9) 80mcg
of drug was administered, and the placebo received PBS. Two weeks after the
drug group had an additional 40mcg of drug administered to insure the
maintenance of the effect. all mice were sacrificed at 4 weeks post-injection for
subsequent examination.

Isolation and preparation of mouse GMSCs:
Adult mice were used to harvest gingival tissue. A single suspension of gingival
tissue was processed for all nuclear cells (ANCs, 15×106) from mice gingiva was
seeded in 10 cm culture dishes (Genesee) then incubated at 37 ℃ with 5% CO2.
After 48 hours, non-adherent cells were removed, and adherent cells were cultured
for additional 14 days in alpha minimum essential medium (α-MEM, Invitrogen)
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supplemented with 20% fetal bovine serum (FBS), 2 mM L-glutamine (Invitrogen),
55 μM 2-mercaptoethanol (Invitrogen), 100 U/ml penicillin and 100 μg/ml
streptomycin (Invitrogen). Passage one and two mouse GMSCs were used in for
cell infusion. GMSCs were tested for common MSC markers CD90 CD105, and
SCA-1 as shown in Fig.5. Cells were prepared for infusion and (2X105) cells were
prepared in sterile 200 μl phosphorus buffered saline (PBS) for each mouse and
injected as an infusion systemically via the tail vein.

CD105/DAPI

Sca-1/DAPI

CD90/DAPI
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Figure 5. GMSC’s expression of common MSC markers. Immunostaining
images showing the expression of common MSC markers CD90, CD105, and
SCA-1 by GMSCs, these markers are amongst methods used to identify
Mesenchymal stem cells. Scale bar, 50 μm.

Computed Microtomography and analysis of datasets:
To analyze the Bone Mineral Density (BMD) and Total Bone Volume (BV/TV). The
femurs and mandibles of mice were harvested at sacrifice then fixed in 4%
paraformaldehyde solution, femurs were then scanned using a desktop highresolution Scanco μCT35 scanner (Scanco Medical AG, Bruttisellen, Switzerland).
The scanning of specimens was standardized to a measurement voxel size of 20
μm at 70kVp and 200 μA. Datasets were reconstructed, and images were analyzed
using the system-provided by the manufacturer (Scanco Medical). Values were
obtained for BMD, and total bone volume.

Histological and histomorphometry analysis:
Femurs and mandibles were fixed in 4% paraformaldehyde for 48 hours then
decalcified with 10% EDTA (pH 7.4) for three weeks undergoing a twice-weekly
change of EDTA to maintain the exposure of femurs to 7.4 pH levels. Following
decalcification, paraffin embedding was completed, then ten μm thick sections
were produced using a microtome and prepared for staining. The first stain
selected for both mandibles and femurs, was the Hematoxylin and Eosin (H&E)
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stain in order to quantify the trabecular bone percentage in the distal metaphyseal
region of the femurs, as well as the retromolar area distal to M3 in the mandibles.
Results are reported in the form of trabecular bone percentage in relation to the
total standardized area of interest (%/area). Further testing for femurs alone
includes Tartrate-resistant acid phosphate (TRAP) staining assay to label TRAP+
cells. TRAP staining kit was purchased from (Sigma-Aldrich), and samples were
prepared by deparaffination then stained according to manufacturer instructions.
TRAP staining images were also acquired from the distal metaphyseal region of
the femur. The results are shown as the number of osteoclasts per square
millimeter of bone surface area (N.Oc/BS). For dynamic bone histomorphometry,
double calcein labeling was utilized, the mice were intraperitoneally injected with
calcein (Sigma, 15 mg/Kg body weight) which was prepared in 2% sodium
bicarbonate solution at two intervals 13 and 3 days before sacrifice. After sacrifice,
femurs were fixed n 4% paraformaldehyde for 48 hours then decalcified with 10%
EDTA (pH 7.4) for a period of two weeks and samples were prepared for cryosectioning and slides were created and mounted with fluoroshield mounting
medium with DAPI (Ab 104139) and pictures were obtained for the bone dynamic
histomorphometry analyses for MAR. Mineral apposition rate is the distance
measured between the two labels divided by the time between the two IP
injections.
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In vivo Oil red O staining / Fatty marrow analysis:
For the analysis of adipocytes surrounding the trabecular areas of the metaphyseal
region of femurs, they were fixed in 4% paraformaldehyde and decalcified with
10% EDTA (pH 7.4) for a period of two weeks. After that, femurs were prepared
for cryo-sectioning by processing the samples in 15% sucrose in 3 hours, then
30% sucrose overnight. The following day, samples were embedded in 1:1 OCT
and 30% Sucrose for 3 hours, then moved and embedded into OCT solution and
stored in -20 C. Freezing microtome machine was then used to create 12
Micrometer sections. The staining of sections was then completed using the Oil
Red-O solution. Positive areas were quantified under the microscope and
illustrated as a percentage of the total area.

Enzyme Linked Immunosorbent Assay (ELISA):
In order to determine the blood serum levels of the different markers, IFN-γ, IL-17,
ALP, and RANKL, peripheral blood was collected at sacrifice, and the serum was
extracted from blood samples by letting the blood samples sit for one hour then
undergoing the centrifugation process to complete the serum extraction. Samples
were then stored in -20 °C until testing was performed. For ELISA testing, mouse
ELISA MAX™ Deluxe kits for IFN-γ, IL-17, and RANKL were purchased from
(BioLegend), ALP was purchased from G-biosciences (IT5507), and ELISA testing
was performed according to the manufacturer’s instructions for each assay.
Results are shown as levels of markers present in serum in picogram/milliliter.
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Isolation and culture of mouse BMMSCs.
Harvesting of single suspension of bone marrow-derived all nuclear cells (ANCs)
from femurs was completed after sacrifice, and 15×106 cells were seeded in 10
cm culture dishes (Genesee) then incubated at 37℃ with 5% CO2. After 48 hours,
dishes were washed with PBS to remove any non-adherent cells. Adherent cells
were cultured for additional 14 days in alpha minimum essential medium (α-MEM,
Invitrogen) supplemented with 20% fetal bovine serum (FBS), two mM L-glutamine
(Invitrogen), 55 μM 2-mercaptoethanol (Invitrogen), 100 U/ml penicillin with 100
μg/ml streptomycin (Invitrogen). Cells were incubated until experiments were
performed using Passage one and two mouse BMMSCs.

Transplantation of BMMSCs into immunocompromised mice.
After the sacrifice of mice, around 4.0×106 mouse BMMSCs from OVX, GMSCtreated,

and

control

mice

were

incorporated

with

40

mg

of

hydroxyapatite/tricalcium phosphate (HA/TCP) powder (Zimmer Inc., Warsaw, IN,
USA) and subsequently implanted subcutaneously into the dorsal surfaces of
eight-week-old female immunocompromised Prkdcscid mice. The implants were
implanted for a period of twelve-weeks, then mice were sacrificed, and transplants
were harvested. After that, they were fixed in 4% paraformaldehyde then
decalcified with 10% EDTA (pH 8.0) for two weeks in preparation for paraffin
embedding. Ten uM paraffin sections of the transplants were then created using a
microtome, then deparaffinized, rehydrated, and stained with the hematoxylin and
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eosin (H&E) stain. Results are shown as a proportion of the bone formed to the
total area (Bone/total area).

Proliferation capacity analysis / BrdU labeling assay.
BMMSCs were seeded into 8-well chamber slides (Thermo Scientific) with a
concentration of 2×104 per well. After two days of cell culture, A concentration of
(1:100) BrdU labeling reagent (Invitrogen) was added to the medium, after which
the cells were incubated at 37℃ with 5% CO2 for 24 hours. Cells were then fixed
with 70% Ethanol, denatured with 2N HCl, and stained with anti-BrdU antibody
(Invitrogen) overnight at 4℃. The second antibody was incubated at room
temperature for 1 hour, then mounted and counterstained with fluoroshield
mounting medium with DAPI (Ab 104139). The positive cells from four fields per
sample were quantified under microscopy and presented relative to the total
number of cells. (positive/total cells).

In-vitro osteogenic differentiation capacity analysis.
The culture of BMMSCs was done under osteogenic inductive conditions with a
twice/week change of the medium. The growth medium composed of 2 mM βglycerophosphate (Sigma-Aldrich), 100 μM L-ascorbic acid 2-phosphate (Wako),
and 10 nM dexamethasone (Sigma-Aldrich). After four weeks of osteogenic

23

induction, matrix mineralization was detected by 1% Alizarin Red (Sigma-Aldrich)
staining or cells of other wells were lysed for protein isolation and examination of
osteogenic gene expression. For Mineralized nodule formation, stained positive
areas were quantified using NIH ImageJ software and shown as a percentage of
the total area (%/Total area).

In-vitro adipogenic differentiation capacity analysis.
BMMSCs were cultured under adipogenic inductive conditions. The adipogenic
medium contained 500 nM isobutyl methylxanthine (Sigma-Aldrich), 60 μM
indomethacin (Sigma-Aldrich), 500 nM hydrocortisone (Sigma-Aldrich), 10 μg/ml
insulin (Sigma-Aldrich), and 100 nM L-ascorbic acid phosphate. Eight days after
adipogenic induction, wells were stained with Oil-red-O stain (Sigma-Aldrich) for
quantification of adipocytes, and positive cells were counted under a microscope
and shown as a percentage of the total cells (%/total number of cells). Additional
good sets were also lysed for protein collection in order to examine adipogenic
gene expressions.

Western immunoblotting.
After cells are washed using PBS and lysed in the RIPA lysis buffer system with
protease and phosphatase inhibitors (Santa Cruz). Protein levels were then
quantified using PierceTM BCA Protein Assay Kit (Thermo scientific). 20 μg of
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proteins were separated by SDS-PAGE (Invitrogen) and transferred to 0.2 μm
nitrocellulose membranes (Millipore). Then the membranes were blocked using a
5% non-fat dry milk and 0.1% Tween-20 for a period of one hour, followed by
overnight incubation with primary antibodies diluted in blocking solution. Antibody
to PPARγ (sc-7196) was purchased from Santa Cruz Biotechnology, Inc. Antibody
to LPL (PA5-47033) was purchased from Thermo Fisher Scientific. Antibodies to
RUNX2 (12556) were obtained from Cell Signaling Technology. Antibodies to ALP
(ab108337) was purchased from Abcam, and β-Actin (A5441) were purchased
from Sigma-Aldrich. The membranes were then washed and incubated for one
hour in HRP-conjugated secondary antibody (Santa Cruz) diluted in blocking
solution. Immunoreactive proteins were detected using SuperSignal™ West Pico
PLUS Chemiluminescent Substrate, SuperSignal™ West Femto Maximum
Sensitivity Substrate (Thermo) and Autoradiography Film (Labscientific, inc).

Flow Cytometry.
After mice were sacrificed, T-cells were collected from spleens. T cells were
extracted by processing spleens and treating them with ACK buffer for red blood
cells removal (Lonza, Switzerland), after that isolated T-cells were incubated for
an hour on ice with 1ug/100ul of PerCP anti-mouse CD4 Antibody (100538,
BioLegend), then for the T-reg testing, an additional 2 ug of APC anti-mouse CD25
(102012, BioLegend) was added as well. FoxP3 staining buffer kit was used to Fix
and

permeabilize

the

samples

overnight

using

Intracellular

Staining
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Permeabilization Wash Buffer (BioLegend). Cells were then stained with 2ug of
either PE anti-mouse FoxP3 (320008, BioLegend) for T-regs, or with APC antimouse IFN-γ for Th1 (505810, BioLegend) for 30 minutes in the dark at room
temperature Then washing with FACS buffer was carried out. After that, all
samples were analyzed using FACSCalibur with CellQuest software (BD
Bioscience).

Immunofluorescent microscopy.
To test the GMSCs expression of MSC markers CD90, CD 105, and SCA-1. The
anti-mouse CD-90 antibody was obtained from Abcam (ab3105), anti-mouse CD
105 antibody was obtained from BD Biosciences (550546), and anti-mouse SCA1 antibody was also obtained from BD Biosciences (553334). For immunostaining
of PD-L1 expression. PD-L1 antibody (#MA5-29672) was obtained from
ThermoFisher Scientific. The samples were then incubated with the obtained
specific or isotype-matched first antibodies (1: 200) overnight at 4 °C, and then the
next day stained with the second antibody according to the manufacturer’s
instructions. Slides were mounted using Fluoroshield Mounting Medium with DAPI
(Abcam). Pictures are shown for illustration purposes.
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siRNA transfection.
For mechanistic testing, an additional treatment group of OVX mice treated with
PDL-1 knockdown GMSCs was assigned and In vitro siRNA was performed,
GMSCs (0.8×106) were seeded in 60 mm culture dishes and treated with Pdcd1L1 siRNA (SC-39700, Santa Cruz) or vehicle siRNA control (Santa Cruz) with
lipofectamine reagent (Invitrogen), according to the manufacturers’ instructions.
After successful transfection was achieved, and the protein expression level is
verified with western immunoblotting, siPdl1 cells were collected and used for
infusion into the siPdl1 mice group.

T-cell apoptosis assay
GMSCs or siPdl1 GMSCs (0.2X106) were seeded in a 24-well culture plate
(Corning) containing Dulbecco’s Modified Eagle’s Medium (DMEM; Lonza, Basel,
Switzerland) with 10% heat-inactivated FBS, 50 μM 2-mercaptoethanol, 10 mM
HEPES, 1 mM sodium pyruvate (Sigma-Aldrich), 1% non-essential amino acid
(Cambrex, East Rutherford, NY, USA), 2 mM L-glutamine, 100 U/mL penicillin, and
100 mg/mL streptomycin. After incubation of GMSCs for 24 h, Spleens from
wildtype were harvested and processed ACK buffer for red blood cell removal
(Lonza, Switzerland) and extraction of T-cells. After isolation of T-cells, (1X106) Tlymphocytes were pre-stimulated by seeding them in anti-mouse-CD3ε (100331,
BioLegend) antibody with a concentration of 5 μg/mL and soluble anti-mouseCD28 (122004, BioLegend) antibody with a concentration of 2 μg/mL. After 2-3
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days of T-Cell activation and confirming aggregation and growing was achieved.
T-Cells were then directly loaded onto WT GMSCs or siPDL1 GMSCs and cocultured for three additional days. Additional wells for control contained plated Tcells only in medium with no cells. After that, apoptotic T-cells were detected by
staining with a CD3 antibody, followed by the use of the Annexin-V Apoptosis
Detection Kit (BD Biosciences, San Jose, CA, USA) and then samples were run
and analyzed by the use of a FACSCalibur flow cytometer equipped with CellQuest
software.

Statistics:
All the data we have shown were expressed as the mean ± SEM. Statistics were
performed using the software SPSS V.26. (IBM corporation. Armonk, New York)
Comparisons between two groups were analyzed using the independent two-tailed
Student’s t-tests. As for the comparison between > two groups were analyzed in
IBM SPSS V.26 using one-way ANOVA/Fisher LSD. P-values less than 0.05 were
considered statistically significant.
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Results

A single infusion of GMSCs successfully improved the bone phenotype of
the ovariectomized mouse model

To explore the therapeutic effects of a GMSC transplantation on the OVX
mouse, an OVX disease model for treatment was established. The timeline of the
treatment consisted of obtaining 8-week-old mice from Jackson labs, the mice
would be then assigned to 3 different groups. After allowing mice to acclimate into
their groups for a week. An ovariectomy procedure would be completed to 2/3
groups, the OVX group and the GMSC-treatment group. Mice would then be
allowed a period of two weeks for the osteoporosis associated with ovariectomy to
develop. After two weeks the GMSC treatment group would receive a single GMSC
transplantation. After 4 weeks of the transplantation, all mice would be sacrificed
for experimentation purposes. The computed microtomography analysis of mice
femurs (Fig.6) reveled a significant deterioration in the bone phenotype of the OVX
mice in comparison to the negative control group as shown by a decrease in the
measurements of bone mineral density (BMD), total bone volume (BV/TV),
Connectivity density (Conn.D) as well as an increase in Structure Model Index
(SMI) values. This reported effect validates the OVX osteoporosis model and
provides additional assurance of the validity and the effect of ovaries removal on
bone. On the other hand, our group of interest, the GMSC-treatment group showed
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that a one-time GMSC transplantation intravenously produced a marked
improvement in the bone phenotype of mice femurs as seen by the elevation in the
bone BMD, total bone volume, Conn.D values, as well as the decrease in SMI
values.
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Figure 6. Computed microtomography analysis of femurs. (A) Images from
the scanned femurs showing difference in trabeculation between different groups.
(B) Bone mineral density measurements revealing improved bone phenotype in
GMSC-treatment group in comparison with OVX group. (C) Total bone volume
measurement also showing an improvement in the GMSC-treatment group when
compared with OVX. (D) Conn.D measurement values of different groups. (E) SMI
measurements of study groups.
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To further investigate the effects of ovariectomy and GMSC treatment of the
bone phenotype in the femurs. Histological analysis of the femurs was completed
to analyze the trabeculation levels of distal metaphyseal regions. Our H&E analysis
indicated

a

similar

outcome

and

mirrored

the

finding

of

computed

microtomography of significant improvement in the distal femur trabeculation
which is seen the GMSC group when compared with the OVX group (Fig.7).
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Figure 7. Histological analysis of femurs. H&E staining of distal femoral
metaphyseal region showing less trabeculation levels of the ovariectomized group
in comparison to both the control and GMSCs-treated group. Scale bar, 500 μm.
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To test whether the osteoclastic activity would be evaluated in bone of those
mice, we further examined the effect of GMSCs transplantation on the number of
osteoclasts in femurs collected from study groups, we found that the number of
osteoclasts is markedly reduced in the control group when compared to the
ovariectomized mice, this reduction of osteoclast number is also seen after the
GMSCs transplantation, this was tested through the observed decrease in number
of Tartrate-Resistant Acid Phosphatase positive cells (TRAP) (Fig.8).
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Figure 8. Trap+ cells analysis of femurs. Trap+ cells staining shows a significant
increase in Trap+ cells in the ovariectomized mice group in comparison to both the
control and GMSCs-treated groups. Scale bar, 100 μm

To further test whether there was fatty marrow presence in femurs, Oil red O
staining was utilized for this test. Our results reveal the presence of higher Fatty
marrow levels in the femurs of the OVX group in comparison with the control group.
The GMSCs-treated group femurs show a significantly reduced fatty marrow area
in comparison to OVX group (Fig.9). We then moved to measure the bone
formation rate in femurs by performing a calcein double labeling assay aimed at
determining the daily rate of bone formation, we found that the control group had
the highest bone formation rate as indicated by the double labeling of calcein, the
OVX group on the other hand showed the lowest mineral apposition and GMSCstreated group showed a significantly higher level of MAR than OVX group (Fig.10).
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Figure 9. Oil-Red-O staining/in-vivo analysis of fatty marrow. Fatty marrow
levels as tested by Oil-Red-O staining show an increase in the levels in the OVX
group when compared with the control group. The fatty marrow level is also
reduced in the GMSCs-treated group when compared to the OVX group. Scale
bar, 100 μm.
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Figure 10. Dynamic bone histomorphometry. The mineral apposition rate was
tested by calcein double labeling showing an increased MAR in control and GMSCtreatment groups when compared with the OVX group. Scale bar, 50 μm.
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After testing the effect of transplantation on the femurs of mice, we next
explored the effect of OVX and GMSCs transplant in the mandibles of mice. The
computed microtomography scans and analysis of the retromolar area distal to M3
in mice mandibles reveled a significant decrease in the bone phenotype of the
OVX mice in comparison to the control group as shown by a decrease in the
measurements of BMD and BV/TV mirroring the effect seen in femurs. The GMSCtreatment group as well showed a marked improvement in the bone phenotype of
the mice mandibular jawbone when compared to the OVX group (Fig.11 A-C). This
is further confirmed by H&E stain and the analysis of the trabeculation levels in
retromolar area of mandibles showing the same trend as the one seen in the
computed microtomography (Fig.12).
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Figure 11. Computed microtomography analysis of mandibles. (A) Images
from the scanned mandibles showing difference in trabeculation between different
groups. (B) Bone mineral density measurements revealing improved bone
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phenotype reflected in GMSC-treatment group mandibles in comparison with OVX
group. (C) Total bone volume measurement also shows an improvement in the
GMSC-treatment group when compared with OVX.
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Figure 12. Histological analysis of mandibles. H&E staining of retromolar area
of M3 showing less trabeculation levels of the ovariectomized group in comparison
to both the control and GMSCs-treated group. Scale bar, 500 μm.
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We next explored the effect of the transplantation on blood serum levels of different
inflammatory and osteoclast markers. We saw that levels of Serum IFN- γ, and IL17 is markedly decreased in the GMSC treated group compared to the OVX group
which is in turn significantly higher in expression when compared to the control
group mice (Fig 13.A, B). Osteoclast marker RANKL was also significantly
decreased in the GMSC treated group (Fig 13.C). These Elisa results suggest that
GMSC infusion successfully reduced the inflammation in the ovariectomized mice
and downregulated the osteoclastic activity. Additionally, Serum ALP levels were
measured in the blood of mice after sacrifice and show a similar trend of a marked
increase in serum ALP in those mice of the OVX group when compared to the
control group, the level of ALP was seen less in the GMSCs-treated group than
OVX but this decrease is not of significance (Fig 13.D).
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Figure 13. Blood serum markers analysis.

(A). IFN-γ levels were overly

expressed in the serum of OVX mice as seen by the Elisa testing, the control group
possessed the lowest levels of IFN-γ expression, and GMSCs treatment
significantly reduced the expression versus the OVX group. (B). IL-17 level was
expressed at about 100pg/ml in the ovariectomized mice blood serum, this was
significantly less in the control group and the GMSCs treatment significantly
reduced the expression level compared to OVX group. (C). RANKL blood serum
levels in the OVX mice was almost double the level found in the control mice blood,
and the GMSCs treatment reduced the blood serum level of RANKL. (D). ALP
levels in blood serum tested showing a significant increase of ALP expression in
serum of OVX mice when compared with the control mice, ALP is mildly decreased
in GMSCs treated mice when compared to OVX mice.

GMSCs transplantation into OVX mice rescued the function of the
endogenous population of BMMSCs.
After addressing our first aim of the study where It was hypothesized that
the ovariectomy would lead to significant bone loss and that the single
transplantation of GMSCs would improve that osteoporotic bone phenotype. Next
we hypothesized that the GMSCs transplantation into the OVX mice would improve
the function of the endogenous population of BMMSCs. This part of the study
aimed at examining the effects of OVX on the BMMSCs of mice and how GMSCs
transplantation influences that effect. To run functionality measuring in-vitro
experiments, the collection of mice BMMSCs from the three different groups was
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completed after sacrifice at 15 weeks. Several experiments were performed in
order to form a generalized idea about the functional capacity of BMMSCs and
what would a transplantation achieve. This included analyzing the ability of
harvested cells to form Colony forming unit-Fibroblasts (CFU-F) by performing a
CFU-F assay, measure the ability of the cells to proliferate utilizing a cell
proliferation assay, testing their adipogenic differentiation capacity with the
measurement of their expression levels of adipogenic proteins Lipoprotein Lipase
(LPL) Peroxisome proliferator-activated receptor gamma (PPAR-γ), testing of their
osteogenic differentiation capacity with the measurement of their expression levels
of osteogenic proteins Runt-related transcription factor 2 (RUNX2), Alkaline
Phosphatase (ALP), and finally by further testing the ability of BMMSCs harvested
from mice to form new bone by transplanting them into immunocpromised mice
after being mixed with particulate ceramic scaffold.

First test after harvesting the BMMSCs from mice, a simple experiment was
completed to determine the ability of the cells harvested to form colonies. A CFUF assay was completed to examine the formation of colonies. While there is no
significant difference observed in the abilities of different groups, the BMMSCs
harvested from the OVX group showed the highest number of colonies formed,
and while the negative control group showed the lowest ability to form colonies,
the GMSCs group lies in between both groups in terms of ability to form colonies
as shown in (Fig.14).
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Figure 14. CFU-F Assay. Analysis of colony formation abilities of cells from
different groups shows OVX possess the highest capacity of CFU-F.

After verifying the ability and measuring the capacity of BMMSCs to form
CFU-F’s as do MSCs. we examined the proliferation capacity of mouse BMMSCs
trying to measure their division and doubling abilities. We saw that cells from the
OVX group had a significantly higher proliferation rate as shown by an increase in
BRDU-positive-cells, this elevation in proliferation capacity is not seen in the
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GMSC-treated group as it was of reduced proliferation compared to OVX and at
an almost comparable rate to those of the control group (Fig 15).
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Figure 15. BrdU proliferation assay. Analysis of proliferation capacity of cells
from different groups shows BMMSCs from GMSC-treated mice has a proliferation
rate comparable to the control while the BMMSCs from OVX mice showed the
highest proliferation rate. Scale bar 50 μm.
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In the testing of osteogenic differentiation potential of BMMSCs. The OVX
group showed a significant reduction in osteogenic differentiation capacity, while
the GMSC-treated group showed a significantly higher potential as shown by the
mineralized nodules formation evaluated by Alizarin red staining (Fig.16), the
decrease in OVX osteogenic potential is accompanied by a decrease of Runx2
and ALP expression, On the other hand an increase in the expression is seen in
both GMSC-treated and control groups as assessed by western blot analysis
(Fig.17).
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treated mice has a markedly higher osteogenic differentiation capacity than the
BMMSCs from OVX mice.
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Figure 17. Osteogenic proteins expression levels. Protein level analysis reveal
that levels of RUNX2 and ALP proteins are expressed at higher levels in the
BMMSCs from GMSCs-treated mice when being exposed to osteogenic inductive
conditions, whereas those from OVX group express the same proteins at
significantly less level.
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Furthermore, when finished testing the osteogenic differentiation capacity,
the adipogenic differentiation potential of BMMSCs was also evaluated after
inducing the cells and staining them with Oil-red-O staining, the BMMSCs of OVX
group mice showed a significantly higher adipogenic differentiation potential when
compared with BMMSCs from both the control and GMSC-treated groups (Fig 18).
This was also further verified by the observed increase in the levels of the
adipogenic proteins PPAR-G and LPL in the OVX group. These proteins were
expressed by BMMSCs from control and GMSC-treated mice as well but at a
significantly reduced level (Fig 19).
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Figure

18.

Adipogenic

differentiation

capacity

assay.

Adipogenic

differentiation capacity of cells from different groups shows BMMSCs from OVX
mice having a markedly higher potential for adipogenic differentiation than those
from BMMSCs of control or GMSC-treated mice. Scale bar 50 μm.
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Figure 19. Adipogenic proteins expression levels. Protein level analysis reveal
that levels of LPL and PPAR- γ proteins are expressed at significantly higher levels
in the BMMSCs from OVX mice when being exposed to adipogenic inductive
conditions, whereas those from both GMSC-treated and control groups express
the same proteins at significantly less level.
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In the last part of determining the influence of OVX and GMSC treatment
on the function of BMMSCs, we wanted to test the abilities of BMMSCs from our
groups to form new bone in vivo. The test involved using immunocompromised
mice and the implantation of BMMSCs from test groups to determine their bone
formation rates after incorporating them into HA/TCP grafts. When analyzed, grafts
from GMSCs-treated and control group exhibited significantly higher level of new
bone formation in comparison to OVX groups (Fig.20).

HA/TCP

BONE

BONE
HA/TCP

BONE
HA/TCP

In-vivo bone formation
(% / total Area)

Control

GMSC

OVX
60
50
40

**

*

30
20
10
0

Figure 20. In-vivo bone formation capacity assay. Testing of the bone formation
capacity revealed higher bone formation observed in those BMMSCs from control
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and GMSC-treated mice, grafts containing BMMSCs from OVX mice show a
severe deficiency in the ability to form new bone. Scale bar, 20 μm.

These results and findings of our functional testing involving BMMSCs of
study groups suggest that the endogenous BMMSs population harvested from the
OVX mice group were of significantly compromised function in all the experiments
completed in this part. This function is of normal expected levels in the mice of the
control group. The BMMSCs from the GMSCs-treated mice revealed there was
and significant improvement in function and the BMMSCs were rescued as a result
of the GMSC transplantation.
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Mechanistic Investigation
GMSCs effect in the OVX mouse model is independent of Fas/FasL cell death
pathway
To test the mechanism behind GMSCs effect in the OVX mouse model.
First, we tested a potentially involved pathway. New groups to test FASL/FAS
pathway are shown in (Fig.21).
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Figure 21. FAS/FASL pathway testing group assignment. (1) Mice not
undergoing ovariectomy procedure, nor transplantation. (2) Mice undergoing
ovariectomy procedure, but no cellular transplantation. (3) Mice undergoing
ovariectomy procedure, then a single transplantation of GMSC. (4) Mice
undergoing ovariectomy procedure, then 1X transplantation of FAS deficient
GMSC obtained from LPR mice (5) Mice undergoing ovariectomy procedure, then
1X transplantation of FASL deficient GMSC from obtained GLD mice.
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Following the same outline as previously describe in Fig.4 and after the
experiment concluded and mice were sacrificed, new femurs were scanned and
analyzed. the compute microtomography images and analysis also revealed a
significant deterioration in the bone phenotype of the OVX mice in comparison to
the negative control group as shown by a decrease in the measurements of bone
mineral density (BMD), total bone volume (BV/TV). While a GMSCs treatment
-/-

-/-

improved the bone phenotype in the OVX mice, so did Fas and FasL GMSCs
(Fig.22).

Control
OVX
GMSC
-/-

Fas GMSC

-/-

FasL GMSC

56

50

BV/TV (%)

40

NS
30

**
*

20

**

*

10

0

500

NS

**

3

BMD (mg/cm )

400

300

200

*

*

**

100

0

Figure 22. Computed microtomography analysis of Fas-/-, FasL-/- GMSCs
treatment. Femurs of Fas-/-, FasL-/- GMSCs show similar effect in BMD and BV/TV
values as that observed as an improvement of the phenotype of the femurs of
GMSC-treatment group.
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Additional analysis of femurs further revealed that the trabeculation levels
of those from mice treated with Fas-/-, and FasL-/- GMSCs are similar to those
treated with wild type GMSCs (Fig.23) as shown by H&E analysis of the sections
created.
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Figure 23. Histological analysis of femurs. Fas-/-, FasL-/- GMSC treated mice
showing an improvement in the trabeculation levels of femurs compared to the
femurs of GMSC-treatment group. Scale bar, 500 μm

This was further confirmed with TRAP+ cell testing to quantify the number of
osteoclasts in the distal metaphyseal region, we found that TRAP+ cell numbers
are in agreement with the previous finding of trabeculation levels in H&E sections
of Femurs as those of Fas-/-, FasL-/- GMSCs-treatment show a similar level of
TRAP+ cells as WT GMSCs-treated group (Fig.24).
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Figure 24. TRAP+ cell analysis of femurs. Femurs of Fas-/-, FasL-/- GMSCs
treated mice show similar levels of osteoclasts to those of the femurs of GMSCtreatment group. Scale bar, 100 μm.
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The testing of Fas/FasL deficient GMSCs on the bone phenotype showed
a similar effect as the one seen in treatment of mice by wild type GMSCs. This
indicates that GMSCs-mediated effect in the OVX mouse is independent of
Fas/FasL pathway. The next pathway investigated as a pathway to play a potential
role is a similar pathway called PD-1/PD-L1 pathway.

GMSCs influences T-cells in the OVX mice via the PD1/PDL1 pathway
Programmed death-1 (PD-1) is a protein first described by Ishida; it is a member
of the immunoglobulin gene superfamily and plays a role in cell death by apoptosis
(67). PD1 is known to be expressed by T-cells, B cells, as well as other types of
cells. PD1/PDL1 pathways application has been investigated in infections, cancer
therapies and immunotherapies due to its role in immune regulation (68,69).
Investigations of PD-1/PD-L1 pathway show that PD-1 ligation restored immune
tolerance potentially by the suppression of T-cells, inducing their apoptosis as well
as its promotion of T-reg function (70,71) MSCs are also known to express PD-L1
and induce T-cell suppression via the PDL1/PD1 pathway accentuating the
importance of PD-L1 in MSC mediated immunoregulation (72). This prompted us
to propose that PD-L1/PD-1 pathway is of a significant role in GMSCs immunemediated effect in the OVX mice and that GMSCs are directly influencing activated
T-cells leading to their apoptosis (Fig.25). To test and confirm this we formulated
four study groups to examine our theory of PD-1/PD-L1’s pathway involvement
(Fig.26).
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Figure 25. Proposed mechanism involving GMSCs suppression of T-cells.
GMSCs interact with T-Cell via PD-1/PD-L1 pathway and induced T-cell apoptosis.
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Figure 26. Study groups of PD-1/PD-L1 pathway mechanistic investigation.
(1) Mice not receiving ovariectomy, nor transplantation. (2) Mice receiving
ovariectomy but without cellular transplantation. (3) Mice receiving ovariectomy
procedure and a single transplantation of WT GMSC. (4) Mice receiving
ovariectomy and a single transplantation siPDL1 GMSCs.

To verify the knockdown of PD-L1 gene in GMSCs after using siRNA approach to
reduce its expression, protein was analyzed to detect the level of protein
expression (Fig 27).
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Figure.27 Expression levels of PD-L1 protein. Verification of protein levels after
utilization of siRNA approach to the knockdown the expression of PD-L1.
To further verify the successful knockdown, we attempted to test the expression of
the protein utilizing an immunohistochemistry approach to stain and we saw higher
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levels of siPdl1 in the WT GMSCs (Fig 28). After that we used either GMSC or
siPDL1 GMSC to transplant into the OVX mice with same previously followed
timeline (Fig.4), that included sacrifice of mice after 15 weeks for further analysis.
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Figure.28

Immunohistochemistry
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of

PD-L1/MSC

markers

expression levels. PD-L1 protein appears to be expressed at lower rate as seen
by the decreased density in PD-L1 signal in siPdl1 knockdown GMSCs in
comparison to that in WT GMSCs. Scale bar, 50 μm.

After testing whether GMSCs do express PD-L1 and successfully knocking down
its expression, it was then used in treatment. After sacrifice, the femurs from mice
were scanned and analyzed. We saw that siPdl1-GMSCs failed to improve the
trabecular bone phenotype in the OVX mice in comparison to the WT-GMSC
treated group as shown by the μCT scan and analysis the measurements BMD,
as well as BV/TV (Fig.29).
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Figure.29 Computed microtomography analysis of siPdl1 GMSCs treatment.
Analysis of femurs from siPdl1-GMSC treated mice have a marked deficiency in
the trabeculation of the distal metaphysis region just as seen in OVX mice whereas
the WT GMSCs-treated group show a marked improvement.
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In addition to the scans of femurs, Histological analysis was also carried to verify
the trabeculation levels of the distal metaphyseal region. We saw that the
trabeculation in femurs from siPDL1-GMSCs group is significantly compromised
just like those from the OVX mice when compared with those from the GMSCs
treated group (Fig.30).
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Figure.30 H&E analysis of femurs. Trabeculation levels shown to be severely
compromised in the siPdl1-GMSC treated femurs in comparison to WT GMSCs
treated ones, they are further comparable to the femurs from the OVX group. Scale
bar, 500 μm.

Because the trabeculation levels are compromised in the siPdl1-GMSC-treated
femurs, we would expect the osteoclasts to be higher in number in synergy with it.
High osteoclast levels per square millimeter of areas analyzed in femurs lead us
to confirm the defect of siPdl1-GMSCs by their failure to reduce TRAP+ cells in the
femurs (Fig.31).
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Figure.31 TRAP+ cell analysis. TRAP+ cells are of increased numbers in
analyzed areas of femurs from siPdl1-GMSCs treated mice, as well as those from
the OVX group. Scale bar, 100 μm.

Additionally, to test the levels of adipocytes that is associated with osteoporosis in
femurs and the increased risk of fractures. An in-vivo test of the levels of fatty
marrow in the distal metaphyseal region of femurs was completed. Femurs of
siPDL1-GMSCs treated group showed a higher level of fatty marrow as show by
increased levels by Oil Red O positive areas. This increased level of fatty marrow
is also seen in the OVX treated group. GMSC-treated group femurs showed a
significantly lower levels that are comparable to the control group (Fig.32).
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Figure 32. in-vivo femur fatty marrow analysis. An increase in fatty marrow
seen siPdl1-GMSCs treated mice similar to those of OVX treated mice. Scale bar,
500 μm.
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Testing of an Anti-PD-L1 drug therapy in combination with GMSCs infusion
of OVX mice.
After confirming the failure of siPdl1 GMSCs to improve the bone phenotype in the
OVX mice, we wanted to verify that PD-L1 is an immune checkpoint for GMSCsmediated effect seen in the osteoporotic mice. so, we hypothesized that the
administration of an anti-PDL1 drug (Atezolizumab) would block the therapeutic
effect of the GMSCs transplantation and that there would be no improvement in
the bone phenotype after GMSCs treatment. In order for us to test this hypothesis,
we utilized two study groups as shown in (Figure.33) and formulated a timeline for
our experiment (Figure.34) consisting of a double injection of the drug
Atezolizumab in the test group and a placebo in the control group after GMSCs
transplantation. After sacrifice, the mice femurs were collected and scanned with
Scanco MCT35 scanner and the trabeculation levels are shown in (Fig.35). We
also analyzed the BMD of femurs as well as Total bone volume (BV/TV) and we
found a statistically significant difference in both values between the control and
the test groups. This verifies our hypothesis that the drug treatment of
Atezolizumab blocked the therapeutic effect of GMSCs and that PD-L1 is a pivotal
immune checkpoint for GMSCs-mediated effect.
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Figure 33. Study groups of PD-L1 drug therapy investigation. (1) Mice
receiving ovariectomy, GMSCs transplantation, and Atezolizumab drug. (2) Mice
receiving ovariectomy, GMSCs transplantation, and Placebo (PBS).

Figure 34. Experimental timeline of treatment. Ovariectomy procedure done at
9 weeks to designated groups, GMSCs were injected into designated group
intravenously via the tail vein.
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Figure.35 Femur Micro-CT images and analysis of Atezolizumab and placebo
groups. Analysis of femurs shows an increased level of trabeculation in the
placebo group vs Atezolizumab group as shown in BV/TV and BMD values.
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Testing of GMSCs, siPdl1-GMSCs transplantations on subsets of T-cells in
the OVX mice model.
We further tested the immune tolerance levels in the OVX mice treated with
GMSCs and effect of GMSCs on the population of T-cells after the completion of
the treatment period, We saw that at 4 weeks post-transplantation timepoint the
GMSCs treatment had significantly downregulated Th1 and T17 levels in
comparison to the levels seen in those of OVX mice. On the other hand, in siPdl1GMSCs treated mice there was a marked increase in Th1 levels in comparison to
the WT GMSCs treated mice, while there is still an increase in Th17 as well it
wasn’t as prominent as Th17. In addition to Th1, and Th17 levels, GMSCs
treatment also significantly upregulated T-reg expression in the OVX mice and
when testing the expression levels of T-regulatory cells in the siPdl1-GMSCs
treated mice it was matching to those of the OVX mice confirming the failure of
siPdl1 GMSCs to influence the expression of T-cells and the success of GMSCs
in influencing T-cells in the OVX mouse model (Fig.36).
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Figure 36. Flow cytometry analysis of Th-1, Th-17 and T-reg levels. Th-1, Th17 expression and T-reg levels in mice from different groups at sacrifice fourweeks post-transplantation.

Testing of GMSCs, siPdl1-GMSCs ability of inducing T-cells apoptosis invitro.
In order to examine the effect of GMSCs treatment on the population of TCells. We utilized an in vitro approach to test that effect. We harvested T-cells and
activated them then cocultured them in vitro with wild type mice GMSCs, or siPDL1
GMSCs. T-Cells were then collected, and an Annexin V apoptosis assay/ flow
cytometry analysis was completed. We noted that in after the 3 days of coculture,
the apoptosis rate of T-cells only group was almost at 5%. The T-Cells collected
from wells cocultured with GMSCs showed an apoptosis rate that is significantly
higher at almost 30%, while the T-Cells harvested from the wells where they were
cocultured with siPdl1 was significantly lower at around 19%. These findings
confirm the ability of GMSCs to induce T-cell apoptosis as well as the finding
reported previously that siPdl1 GMSCs are defective and unable to effectively
induce T-cell apoptosis (Fig.37).
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Figure 37. T-cell apoptosis assay. Coculture of siPdl1 and WT GMSCs with Tcells shows a higher ability of WT GMSCs to inducing T-cell apoptosis when
cocultured with T-cells than the siPdl1 GMSCs.
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Discussion
Osteoporosis is a skeletal system disorder that could occur in all ages at any given
population resembling a great worldwide concern. The disease is also of a higher
level of concern in particular in those populations of older men, and
postmenopausal women as the osteoporosis-related fractures associated with the
disease are of tremendous magnitude on healthcare systems. The treatment takes
a toll on institutional financial resources. These fractures are also known to be of
a higher risk of occurrence in women than in men (1,73,74). For the treatment of
the disease, several interventional approaches are available to manage and treat
those patients diagnosed with osteoporosis or at risk of developing it. Amongst the
available and widely accepted treatment options are either pharmacological or
non-pharmacological based treatments. The Non-pharmacological interventions
are revolved mainly around dietary and lifestyle modifications such as the increase
of calcium or vitamin D intake to achieve peak bone mass in an individuals’ growth
through life as well as the involvement of exercise routines, these interventions
resembling more of a preventive approach and are aimed at reducing the risk of
fractures (1).
On the other hand, pharmacologic interventions for diagnosed individuals
include the utilization of antiresorptive agents in treatment such as the
bisphosphonates class of medications used to reduces bone resorption by mainly
increasing the apoptosis rate of osteoclasts (21). Different bisphosphonates class
drugs that are used for the treatment of osteoporosis are effective in reducing bone
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resorption rates (22-24), but their use has been associated with both short- and
long-term adverse effects, with the latter including BRONJ, atypical femur
fractures, and concerns of exaggerated suppression of bone turnover rates
(25,26,75). Another class of antiresorptive agents available for use are estrogens
and selective estrogen receptor modulators (SERMs) (27,28). their use as
hormonal replacement therapy in treatment has been associated with reports of
breast cancer and cardiovascular events (29,30). The third class of
pharmacological, interventional drugs used in the treatment of osteoporosis are
anabolic agents, they are different from the mechanism of action used by
bisphosphonates as they act on the enhancement of bone formation rather than
decreasing the bone resorption rates and an example of anabolic agents is the
Parathyroid hormone (PTH). It is a well-known and potent inducer of bone matrix
synthesis; it increases osteoblast activation and decreases their apoptosis rates
(31). The use of the anabolic agent PTH in treatment of postmenopausal
osteoporosis is deemed beneficial but the expense associated with the drug is a
limiting factor for its use, in addition to that investigators found there was an
incidence of osteosarcoma associated with its use in a two years animal study
while testing different variety of doses leading to the recommendation of a limited
time use (33,76).
Although

the

mentioned

pharmacologic

and

non-pharmacologic

interventions are currently employed as treatment methods for osteoporosis, the
accompanying setbacks with their use could be considered a limitation to the
effective utilization of these treatments. This increases the need for the
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development of treatment approaches in the field as alternative methods to
manage and treat the skeletal system disorder osteoporosis. Systemic infusions
and cellular therapy investigations in disease models of chronic nature are of a
wider potential for application nowadays; this is shown by the remarkable numbers
of clinical trials investigating several diseases in different trial phases ranging from
phase I to phase VI clinical trials. The investigations include mainly evaluating the
use of MSC cell therapy in different fields like cardiovascular disease, autoimmune
disease (i.e., SLE, GVHD, and SS), cutaneous skin defects, bone defects, and
liver diseases (42). These present methods of investigation and the advancements
of cell therapy applications in the field of research has made the search for a cell
therapy-based approach popular. If a cellular infusion is effective therapeutically in
the improving the bone phenotype of osteoporosis elevating its mass potentially
without the adverse effects associated with those of pharmacological agents, it will
lead to opportunities exploring and applying different approaches for treating
osteoporosis in addition to a potential in the treatment of various types of immunerelated diseases. MSCs in bone research are also deemed popular because of
their abelites to directly replace damaged multiple tissues like that of bone,
effectively influence cellular mechanisms of recovery, and exert a robust
immunoregulatory effect (35,77-79).
In our investigation, the estrogen deficiency-related osteoporosis is an
inflammatory disease in nature due to the increase in overall inflammation in the
body caused by removal of ovaries or menopause, which is supplemented by an
increase in the pro-inflammatory cytokines caused by estrogen deficiency and the
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involvement of T-cells that is seen in ovariectomized mice (80-82), this background
of the disease along with the immunomodulatory properties and multipotent
differentiation potentials of MSCs impelled us to explore the therapeutic and
immunomodulatory effects of a dental tissue-derived population of mesenchymal
stem cells in a small animal model (OVX) which is a well-established model in bone
disease research field (83). While the therapeutic outcome for our cell therapy
approach can be investigated as a preventative measure against any OVX
associated bone loss, and as a transplantation of SHED has already successfully
prevented early phases of bone loss in OVX mice (59), we wanted our
experimental timeline for the disease model to allow an adequate period for the
defectiveness in the bone to develop. As for the reason we chose to use of
GMSCs; they are available after birth, and their application has been explored in
multiple disease models previously, and they have proven efficient in the
immunomodulation of the host immunologic environment, their effect on the bone
phenotype and application in the osteoporotic disease model has not been
evaluated. Furthermore, additional reasons we chose to utilize mesenchymal stem
cells from the gingiva in our study is that they hold several advantages over other
sources of MSCs. They not only possess immunomodulatory properties and
multipotent differentiation potential, the procedure of obtaining GMSCs from a
source and their harvesting hold less morbidity in comparison to other types of
MSCs, and it is high in proliferation.
In our investigation we found that a single systemic infusion of GMSCs was
successful in causing a significant improvement in the osteoporotic bone
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phenotype caused by estrogen deficiency in the OVX mice, this improvement was
seen in the long bones of animals, and it was mainly demonstrated through
studying and analyzing the distal metaphyseal region of the femurs as it has been
reported to be amongst the commonly used methods to asses bone trabeculation
in mice (84). This improvement was also shown in the mandibles of mice as
evaluated by measuring and analyzing the retromolar area distal to M3, revealing
an improvement in GMSCs treated mice mandibles in comparison to the
significantly less trabeculation seen in the OVX mice. In femurs, in addition to our
results showing an elevation of bone trabeculation levels of the distal metaphysis
of femurs, an increase in the total bone volume, a decrease of the numbers of
osteoclasts, a decrease of fatty marrow tissue occurred in femurs, and an increase
in the MAR as measured by double calcein labeling, confirming that the overall
bone phenotype was improved after the systemic infusion of mice. Mandibles also
had a similar effect in the bone trabeculation of the mandibles, as shown by H&E
stain and analysis. In addition to the femurs and mandibles analysis showing an
improved phenotype, the blood serum analysis of mice showed elevated levels of
IFN-γ, IL-17, and RANKL in the OVX mice as it was reported that after estrogen
deficiency occurs, T-lymphocytes play a role in the bone loss (18,19). This
increase was diminished by the infusion of GMSCs which did effectively reduce
the level of these serum markers.
Furthermore, there is a deterioration of the endogenous populations of bone
marrow stem cells in OVX mice, which contributes to the reduction in bone mineral
density (85). Thus, after we confirmed the in-vivo effects of OVX in mice femurs
83

and mandibles, and we observed the improvement in the phenotype as a result of
the GMSCs infusion as well as the reduction seen in some blood serum markers
of inflammation, we wanted to investigate further if the deterioration of endogenous
BMMSCs in OVX mice would be rescued and their function would be improved in
response to the GMSCs infusion by functionally testing those BMMSCs harvested
from animals at the end of our timeline. Our first step in testing was to check the
colony formation ability of BMMSCs and test their ability to form colonies as well
as if there was any difference between the groups, while cells from OVX mice had
a slightly non-significant level of higher colonies formed in vitro than those of
BMMSCs from other groups, this could be potentially explained that those from
OVX mice are higher in colonies formed due to an overactivation or defectiveness
of their BMMSCs leading to higher colonies formation. This trend was similar when
measuring the proliferation capacities of BMMSCs of groups, OVX mice BMMSCs
had a significantly higher level of proliferation, while those from GMSCs-treated
mice had a comparable level of proliferation to those seen in the control group.
The proliferation rate could be an additional confirmation to our explanation that
BMMSCs from OVX mice are in an overactivated stage to compensate for the
defectiveness in comparison with those from control and GMSCs-treated mice.
Furthermore, BMMSCs are multipotent differentiation potential includes their
capacity to be induced to adipogenic, osteogenic, or chondrogenic tissues under
certain conditions and are identified as superior in their osteogenic differentiation
potential (79,86).
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In our study we tested the osteogenic and adipogenic potential of BMMSc
harvested from mice to measure the differentiation potential, we found that those
from the control group have the highest osteogenic differentiation potential and the
lowest adipogenic potential of all groups, on the other hand, BMMSCs that were
harvested from OVX mice had the highest adipogenic differentiation potential and
the lowest osteogenic differentiation potential of all groups. This indicates a higher
adipogenic tissue formation tendency related to those BMMSCs of the OVX mice
and a less capability for osteogenic differentiation. When we looked at BMMSCs
from the GMSCs-treated mice, we found that the differentiation potential was
comparable to those from the control mice with a higher level of osteogenic
differentiation potential than adipogenic differentiation potential. This was further
confirmed by analyzing protein expression levels of adipogenic and osteogenic
markers of BMMSCs undergoing induction by measuring osteogenic markers ALP,
and RUNX2 and adipogenic markers LPL and PPAR-G. Osteogenic markers were
expressed in a markedly higher level in BMMSCs from control and GMSCs-treated
groups than the OVX group. In agreement with the differentiation capacity,
adipogenic markers were highly expressed in BMMSCs from the OVX group, and
that expression was seen less in BMMSCs from the control and GMSCs-treated
groups. These findings suggest that the functionality of BMMSCs was improved
from the GMSCs transplantation and that the defectiveness of BMMSCs cause by
the ovariectomy is rescued. In order to further verify the function of BMMSCs was
rescued, we tested the in-vivo bone formation ability of BMMSCs harvested from
mice through transplanting the cells into dorsal surfaces of immunocompromised

85

mice after mixing them with HA/TCP. We saw that grafts that were incorporated
with BMMSCs from the control or GMSCs-treatment mice had a significantly higher
ability to form new bone when compared to those incorporated with BMMSCs from
OVX mice, which had a significantly lower level of bone formation. These data
showed the rescue of endogenous BMMCSs from the infusion of GMSCs and not
only by in-vitro testing of BMMSCs function, but it was also observed in-vivo after
grafts incorporated with BMMSCs from GMSCs-treated mice showed a higher
level of new bone formation.
After we established the efficacy of GMSCs transplantation and explored
the influence they have on improving bone phenotype and the function of the
endogenous population of BMMSCs. We wanted to test whether there was an
exerted effect of the GMSCs transplantation on the recipients’ T-cell population
and if the mechanism related to improvement seen by GMSCs transplants is due
to its ability to suppress activated T-cells just as its capable of achieving in vitro,
as it’s already known that the T-cell activity is higher in postmenopausal
osteoporosis in both humans and mice, highlighting the role of T-cells in the
osteoporotic bone loss caused by estrogen deficiency (63,87,88). Furthermore,
when it comes to systemic infusions and stem cell therapies, the mechanisms
behind the therapeutic effect and immunomodulation achieved are still in the
process of being fully understood. In our study, we established the presence of a
positive effect from the GMSCs systemic infusion and further investigated possible
pathways involved in the underlying mechanism leading to immune tolerance.
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It is reported in the literature that the immunomodulatory properties
achieved of a systemic infusion using BMMSCs involved the Fas/FasL cell death
pathway, and it was revealed that BMMSCs expressed both FAS and FASL and
that the FAS/FASL pathway is involved in the mechanism behind the BMMSCsmediated therapeutic effect and the induction of T-cell apoptosis which leads to
immunologic tolerance (89). For the cells of the body to undergo apoptosis, there
are multiple known cell death pathways involved. Fas and FasL, a receptor and its
ligand which are members of receptors in the subset of Tumor Necrosis Factor
Receptor (TNF-R) superfamily and a part of the FAS/FASL pathway, also known
as the CD95-CD95L pathway, and plays a significant role in which the immune
system’s programmed cell death by apoptosis is initiated achieving homeostasis
(90,91). Since FasL is a type II transmembrane protein, the proteins forming as a
consequence of its interaction with Fas initiates the Death Inducing Signaling
Complex (DISC) (92,93). and because the Fas/FasL pathway is an identified
method

in

BMMSCs-mediated

induction

of

T-cell

apoptosis

and

immunomodulatory homeostasis, as previously mentioned (89).
We wanted to investigate the FasL/Fas pathway and whether GMSCs
would be similar to BMMSCs, and it would be the pathway involved in the GMSCs
mediated immunomodulatory effect. To test that, we used gingival tissues from
both FAS and FASL deficient mice B6Smn.C3-Faslgld/J and B6.MRL-Faslpr/J to
harvest GMSCs for transplantation.

We tested the effect of FasL or Fas

knockdown GMSCs each separately in-vivo by transplanting them into the OVX
mouse following the same previously mentioned experimental timeline (FIG.4). To
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our surprise, our results and what we observed as a result of the transplantation
after sacrifice was that neither FasL nor Fas knockdown GMSCs had a negative
effect as we expected on the bone phenotype and they both had the same
therapeutic effect as did the wild type GMSCs in the OVX mice, this was tested in
femurs by measuring the BMD, Total bone Volume, bone trabeculation levels, and
osteoclasts numbers. What this revealed to us was that GMSCs-mediated effect
in the OVX mice was not established through the FAS/FASL pathway as seen in
other types of MSCs (i.e. BMMSCs) this could be due to the difference in
harvesting source with GMSCs being a type of dental tissue-derived stem cells
and may mean they possibly use an alternative cell death pathway in the process
of immune regulation or it could be that GMSCs transplantation did not affect the
T-cell population of the host at all and the effect was seen in OVX mice is
independent of any immune response and solely to the ability of GMSCs to directly
differentiate into bone leading to an improvement in the overall bone mass and
function of BMMSCs. After testing the Fas/FasL pathway, we looked further indepth for other potential pathways that may be behind the GMSCs’ effect in the
OVX mice.
Another pathway we came across involves the PD-1 or programmed cell
death one receptor, which is part of the CD28 family, and the PD-1/PD-L1
programmed cell death pathway is a popular cell death pathway in the research
field. It is known to be an important pathway for apoptosis in many cell types,
including T-cells, playing an effective role in immunomodulation, and immune
tolerance as PD-1 has been shown to be expressed by different immune cells,
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including B-cell, activated T-cells, macrophages, dendritic and natural killer cells
(67,68,94). The pathway is also popular in the field of cancer research, and the
reason it is heavily investigated is that the blockade of the PD-L1/PD-1 pathway
exhibits an effect on activated T-cells, and clinical trials have already shown that
anti-PD-1 drugs affected the regression of solid tumors. In addition to that, tumor
cells may use the PD-1 pathway for evading the immune system, but by blocking
the PD-1 pathway, the chance of cancer cells evading the immune system is
eliminated. Clinical trials are underway investigating the targeted therapeutic
blockade of PD-1 and PD-L1, such as the already approved FDA drugs nivolumab
and ipilimumab, which are used for combination therapy of certain types of
melanomas (69,95-97). As for MSCs, It has been reported in the literature that
BMMSCs have the ability to express PD-L1 and directly induced T-cell suppression
via the PDL1/PD1 pathway highlighting the importance of PD-L1 in BMMSC
mediated immunomodulation and immune tolerance through T-cells (72). While
BMMSCs are known to only express PD-L1 and not PD-1, dental tissue-derived
stem cells like DPSCs and SHED are shown to express both PD-1 and PD-L1. For
PD-L1, it has been shown to be expressed in the cytoplasm of the cells, while PD1 is expressed in the membrane of the cells. PD-1 also has an important role in
maintaining neural crest-derived dental pulp MSCs as it has been identified to
participate in proliferation maintenance (98).
Furthermore, as the gingiva contains dental tissue-derived stem cells, and
it also is known to contain roughly 90% neural crest-derived GMSCs and 10% from
the mesoderm, and it had the ability to induce activated T-cell apoptosis in-vitro
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(63). Therefore, we tested the PD-1/PD-L1 pathway, and we hypothesized that
GMSCs being a dental tissue-derived stem cell population expresses PD-L1 like
DPSCs and SHED and that PD-L1 pathway is the pathway in which GMSCs effect
is seen in the ovariectomized mice model. To test this hypothesis, we utilized the
siRNA approach to knockdown PD-L1 in GMSCs and used them for our
transplantation. Our findings revealed that a single siPdl1 GMSCs transplantation
was not successful in improving the bone phenotype in the OVX mice, this was
also tested by scanning the femurs and analyzing the BMD, Total bone Volume,
as well as testing measuring femurs levels of bone trabeculation, osteoclasts
numbers, and fatty marrow levels which were confirmatory to the computed
microtomography analysis of femurs. These data suggested that the effect on the
bone and BMMSCs that we saw as a result of a GMSCs infusion in the OVX mouse
model involves the PDL1/PD1 pathway.
Furthermore, to verify the involvement of PD-L1 in the GMSCs-mediated
effect we utilized the use of an anti-PDL1 drug (Atezolizumab) and tested the effect
on two groups, a wild type GMSCs-treated group receiving a placebo of PBS and
wild type GMSCs treated group receiving two injections of Atezolizumab twice in a
period of four weeks after the GMSCs treatment. The placebo group showed a
significant increase in BV/TV, BMD values as measured and analyzed by
computed microtomography in comparison to the Atezolizumab drug treatment
group, this verifies the involvement of PD-L1 as in immune checkpoint for GMSCs
mediated effect in the OVX mouse model, we utilized the drug Atezolizumab in our
experiment as it has been approved recently by the FDA for treatment in multiple
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cancer types pertaining to the lungs, and breasts in humans, it targets
reestablishing anti-tumor T-cell activity by the blockade of PD-L1 protein which the
expression of decreases T-cell anti-tumor activity (99-101). In our study, by
witnessing a diminished effect of GMSCs infusion on the OVX bone phenotype,
we confirm the role of PD-L1 as an immune checkpoint in the GMSCs-mediated
effect in the ovariectomized mouse model. In addition to that, we tested the
influence of GMSCs and siPdl1 GMSCs on the population of T-cells of mice and
saw that the ovariectomized mice had a markedly higher level of Th-1 and Th-17,
and a lower level of T-regs as determined by FACS. The levels of Th-1 and Th-17
in the GMSCs treated mice were significantly lowered when compared to the OVX
group, and the T-regs where higher. The siPdl1 GMSCs treated mice had a similar
expression of Th1, T-reg to that in OVX mice, and a less of similarity in Th-17.
These data of T-cells subsets confirm the ability of GMSCs transplantation to
reduce the levels of Th-1, Th-17 expression, and elevate T-reg expression leading
to immune regulation. Lastly, when we tested the abilities of GMSCs and siPdl1
GMSCs to induce T-cell apoptosis in vitro, we observed a marked elevation in the
levels and capabilities of WT GMSCs to induce T-cell apoptosis when compared
to those of siPdl1-GMSCs. This further confirms the importance of siPdl1 in the
identified influence of GMSCs on T-cells.
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Conclusions
•

Ovariectomy induced osteoporosis is a valid small animal model
leading to significant deterioration of bone phenotype.

•

A Single transplantation of GMSCs into the OVX model markedly
improved the bone phenotype.

•

A Single transplantation of GMSCs into OVX mice significantly improved
the function of endogenous BMMSC population and rescued them.

•

FAS/FASL pathway is not the pathway of which GMSCs exert its effect in
the OVX mice.

• GMSCs immune-mediated effect in the OVX mice is through PD-L1
immune checkpoint and the influence of transplantation on T-cell
populations leads to immune tolerance.
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